There is a clear unmet need for an effective, well-tolerated therapy to address the physiologic and symptomatic effects of Obstructive Sleep Apnea (OSA). Apnimed is among the first companies seeking to develop oral medications to address the underlying biology of this life-altering illness.

Groundbreaking research at Brigham and Women’s Hospital in Boston paved the way for a pharmacologic treatment of OSA. This work suggested that a once-daily medication taken at night to treat OSA could be a powerful new treatment option in place of continuous positive air pressure devices, often known as CPAP. Apnimed has built upon this exciting research and is leading the way in the development of new pharmacologic treatments to be offered to a broad range of patients with OSA.

ObSTRUCTIVE SLEEP APNEA

Developing a disease-modifying treatment

Once-daily, oral medications for sleep apnea would constitute a major advance

ObSTRUCTIVE SLEEP APNEA

Developing a disease-modifying treatment

Once-daily, oral medications for sleep apnea would constitute a major advance

There is a clear unmet need for an effective, well-tolerated therapy to address the physiologic and symptomatic effects of Obstructive Sleep Apnea (OSA). Apnimed is among the first companies seeking to develop oral medications to address the underlying biology of this life-altering illness.

Groundbreaking research at Brigham and Women’s Hospital in Boston paved the way for a pharmacologic treatment of OSA. This work suggested that a once-daily medication taken at night to treat OSA could be a powerful new treatment option in place of continuous positive air pressure devices, often known as CPAP. Apnimed has built upon this exciting research and is leading the way in the development of new pharmacologic treatments to be offered to a broad range of patients with OSA.

a blocked airway

The Underlying Biology of Obstructive Sleep Apnea

In OSA the muscles that maintain an open upper airway relax during sleep leading to partial or complete pharyngeal collapse. This results in intermittent hypoxemia (low oxygen levels), sleep disruption and long-term cardiac and metabolic morbidity and mortality. Sleep-related muscular relaxation is the key neurological issue leading to OSA – patients suffering from OSA do not experience airway obstructions while awake, even while lying down. In patients with OSA, sleep onset leads to a reduction in neuromuscular activation of the upper airway and a corresponding relaxation of the upper airway and tongue muscles. 

OSA is driven by sleep-related upper
airway muscular relaxation

Full airway control in wakefulness

OSA patients do not experience airway obstructions while awake, even while lying down. The upper airway muscles are innervated and controlled by the hypoglossal motor nucleus in the brain stem which keeps the muscles fully active during wakefulness.

Low muscle tone at night causes obstructions

During sleep, neurotransmitters levels drop, leading to decreases in upper airway muscle tone and airway obstructions. Full obstructions are called apneas, while partial obstructions are called hypopneas.

OSA has serious consequences

Apneas and hypopneas lead to hypoxia and disrupted sleep. OSA is associated with adverse metabolic and cardiovascular outcomes and increased mortality, and can impair work productivity, reduce functional ability, and lower quality of life.

Opening a blocked airway

Addressing the Cause of OSA

By targeting the neurological control and activation of upper airway dilator muscles, we can potentially address the cause of the disease, improve respiration and oxygenation during sleep, and reduce the adverse health outcomes associated with OSA.

AD109 reactivates upper airway
muscles during sleep

Full airway control in wakefulness

OSA patients do not experience airway obstructions while awake, even while lying down. The upper airway muscles are innervated and controlled by the hypoglossal motor nucleus in the brain stem which keeps the muscles fully active during wakefulness.

AD109 is dosed at bedtime

AD109 targets two neurochemical pathways which control the upper airway musculature during sleep via a dual mechanism of action. AD109 would be the first medication indicated to address the disordered nighttime breathing that causes obstructive sleep apnea.

 

Airway muscle tone is maintained

AD109’s dual mechanism of action leads to upper airway dilation and improved respiration and oxygenation during sleep.